# Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

> **NCT02954536** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** trastuzumab
- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT02954536
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-03
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-03-14
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954536, "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02954536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*